Clinical trials
Graft vs Host Disease trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
89 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 8 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 5 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 89 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rabin Medical Center | 7 |
| Hadassah Medical Organization | 4 |
| Sheba Medical Center | 4 |
| Peking University People's Hospital | 3 |
| Central Hospital, Nancy, France | 2 |
| Fairview University Medical Center | 2 |
| Hospital Authority, Hong Kong | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Karolinska Institutet | 2 |
| Medical University of Vienna | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Graft vs Host Disease | 89 |
| Leukemia | 9 |
| Hematologic Neoplasms | 6 |
| Myelodysplastic Syndromes | 6 |
| Leukemia, Myeloid, Acute | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Lymphoma | 4 |
| Recurrence | 4 |
| Anemia, Aplastic | 3 |
| Bronchiolitis Obliterans Syndrome | 3 |
Trials
Showing 1 to 25 of 89. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.